Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* acute myeloid leukemia (AML) (according to the WHO 2008 classification):~  * De novo~ * Secondary AML previously treated with demethylating agents for AML~ * Secondary AML previously treated with demethylating agents for MDS~ * Secondary AML previously treated with high dose lenalidomide for AML (≥ 25mg)~* High Risk MDS:~  * Del (5q)~ * Non-del (5q), previously-treated with lenalidomide.~ * Novo or secondary HR-MDS previously treated with demethylating agents~* White blood cell (WBC) ≤ 10,000~* Age ≥ 60~* Not an immediate candidate for allogeneic stem cell transplantation~* Unwilling or unable to receive conventional chemotherapy~* Prior therapy:~  * with single agent demethylator (5-Azacitidine or Decitabine)~ * with Lenalidomide~* Eastern Cooperative Oncology Group performance status ≤ 2~* Life expectancy \> 2 months~* All study participants must be registered into the mandatory RevAssist program~* Willing and able to comply with the requirements of RevAssist~* Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test 10-14 days prior to study enrollment and again within 24 hours of prescribing lenalidomide~  * Must commit to either continued abstinence from intercourse or begin two acceptable methods of birth control, at least 28 days before she starts taking lenalidomide.~ * Must also agree to ongoing pregnancy testing.~* Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.~* Willing and able to understand and voluntarily sign a written informed consent~* Able to adhere to the study visit schedule and other protocol requirements~Exclusion Criteria:~* Patients with LR-MDS progressing to HR-MDS after low dose lenalidomide or 5-day azacitidine will not be eligible.~* History of intolerance to thalidomide~  -development of erythema nodosum while taking thalidomide or similar drugs~* Known or suspected hypersensitivity to azacitidine or mannitol~* Patients with advanced malignant hepatic tumors.~* Concomitant treatment with other anti-neoplastic agents, with the exception of hydroxyurea~* Previous participation on the VIREL study with the concomitant use of azacitidine plus lenalidomide.~* Anti-neoplastic treatment less than four weeks prior to enrollment, with the exception of hydroxyurea~* Use of any other experimental drug or therapy within 28 days of baseline~* Inability to swallow or absorb drug~* Active opportunistic infection or treatment for opportunistic infection within four weeks of first day of study drug dosing~* New York Heart Association Class III or IV heart failure~* Unstable angina pectoris~* Uncontrolled cardiac arrhythmia~* Uncontrolled psychiatric illness that would limit compliance with requirements~* Known HIV infection~* Pregnant~* Breast feeding~* Lactating females must agree not to breast feed while taking lenalidomide~* Other medical or psychiatric illness or organ dysfunction or laboratory abnormality~* Laboratory abnormalities:~  * Either creatinine ≥ 1.5 mg / dL or creatinine clearance ≤ 50 mL / min~ * Total bilirubin \>1.5 x institutional ULN~ * AST and ALT \> 2.5 x institutional ULN

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azacitidine plus Lenalidomide (Type: EXPERIMENTAL): Patients will receive a single dose of azacitidine 75 mg/m² SC or IV on days 1 to 7, followed by lenalidomide 50 mg PO daily on days 8 to 28 of a 42-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).